CYCN
Cyclerion Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$18.87M
P/E Ratio
—
EPS
$-1.75
Beta
1.75
52W High
$8.48
52W Low
$1.03
50-Day MA
$3.46
200-Day MA
$2.37
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Cyclerion Therapeutics Inc
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery, development, and commercialization of drugs for serious diseases of the central nervous system (CNS). The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | $1.90M |
| Gross Profit (TTM) | 303,000 |
| EBITDA | $-9.58M |
| Operating Margin | -359.20% |
| Return on Equity | -98.20% |
| Return on Assets | -52.30% |
| Revenue/Share (TTM) | $0.49 |
| Book Value | $1.20 |
| Price-to-Book | 3.50 |
| Price-to-Sales (TTM) | 9.93 |
| EV/Revenue | 8.63 |
| EV/EBITDA | 0.56 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -43.20% |
| Shares Outstanding | $4.68M |
| Float | $1.24M |
| % Insiders | 21.02% |
| % Institutions | 70.86% |
Historical Volatility
HV 10-Day
57.04%
HV 20-Day
45.07%
HV 30-Day
52.78%
HV 60-Day
43.67%
HV Rank
—
Volatility is currently expanding
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CYCN and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 8/18/2026